Valneva completes bla submission to u.s. fda for its single-shot chikungunya vaccine candidate

Saint- herb lain (france ) , december 23 , 2 02 2 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announces that it has completed rolling submission of the biologics license application (bla) to the u.s. food and drug administration (fda) for its single-shot chikungunya vaccine candidate, vla1553. valneva is seeking approval of its investigational chikungunya vaccine in persons aged 18 years and above.
VALN Ratings Summary
VALN Quant Ranking